Markov model to assess long-term effects of teneligliptin in treatment of type 2 diabetes mellitus

doi:10.12092/j.issn.1009-2501.2018.01.013

Abstract

Abstract:

AIM: To investigate the long-term efficacy and safety of teneligliptin as dipeptidyl -peptidase Ⅳ(DPP-4) inhibitor for type 2 diabetes mellitus and estimate the long-term efficacy. METHODS: Search the literature in databases of PubMed, The Cochrane Library, Embase, CNKI, Wan Fang, CQVIP and so on. Randomized controlled trials (RCT) of teneligliptin for the treatment of T2DM were collected with time limit from establishment to June, 2017. References and related professional magazine were also retrieved manually. Two researchers independently screened these literatures according to the inclusion and exclusion criteria, extracted basic information and assessed the methodological quality of included studies. Meta-analysis of the indexes was performed by using RevMan 5.3. Evaluate the long-term efficacy by establishing a new Markov model. RESULTS: Five RCTs were collected, including 903 diabetic patients. The results of meta-analysis showed teneligliptin can effectively reduce the main index HbA1c ［SMD=-0.87, 95%CI(-0.99,-0.76), P<0.000 01］ and FPG［SMD=-0.71, 95%CI (-0.85,-0.58), P<0.000 01］, increase the secondary index HOMA-beta ［SMD=0.46, 95%CI (0.33,0.60), P<0.000 01］ than placebo group. And there was significant difference between them (P<0.05). And Markov model showed teneligliptin can decrease the numbers of death. CONCLUSION: As the new kind of hypoglycemic agent, dipeptidyl peptidase-Ⅳ (DPP-4) inhibitor teneligliptin can reduce the blood glucose effectively with no increased risk of hypoglycemia, protect the beta-cell function of type 2 diabetic mellitus and decrease the rate of diabetes complications and death.

Key words: dipeptidyl peptidase-Ⅳ inhibitor, teneligliptin, type 2 diabetes mellitus, systematic review, Markov model

CLC Number:

R587.1

ZHANG Chunyan, FAN Xiaodong, QIN Yuan, KONG Wenqiang, ZHOU Chunyang, DU Biao. Markov model to assess long-term effects of teneligliptin in treatment of type 2 diabetes mellitus[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 65-72.

References

［1］Sharma SK, Panneerselvam A, Singh KP, et al. Teneligliptin in management of type 2 diabetes mellitus［J］. Diabetes Metab Syndr Obes, 2016, 9: 251-260.
［2］Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors［J］. Diabetes Obes Metab, 2016, 18(3): 203-216.
［3］Yassin SA, Aroda VR. Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale［J］.Drug Des Devel Ther, 2017, 21(11): 923-937.
［4］Bryson A, Jennings PE, Deak L, et al. The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension［J］. Expert Opin Pharmacother, 2016, 17(10): 1309-1316.
［5］Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial［J］. Diabetes Obes Metab, 2012, 14(11): 1040-1046.
［6］Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0［M］// Cochrane handbook for systematic reviews of interventions /. Wiley-Blackwell, 2011: 102-108.
［7］Kadowaki T, Kondo K. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus［J］. J Diabes Investig, 2013, 4(6): 576-584.
［8］Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus［J］. Diabetes Obes Metab, 2013, 15(9): 810-818.
［9］Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension［J］. Diabetes Obes Metab, 2014, 16(5): 418-425.
［10］Kim MK, Rhee EJ, Han KA, et al. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial［J］. Diabetes Obes Metab, 2015, 17(3): 309-312.
［11］Hong S, Park CY, Han KA, et al. Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo‐controlled phase III trial［J］. Diabetes Obes Metab, 2016, 18(5): 528-532.
［12］高雯雯. DPP-4抑制剂联合二甲双胍治疗T2DM的短期效果及长期药物经济学评价［D］. 山东大学, 2016.
［13］United Kingdom Prospective Diabetes Study Group. Blood glucose control with metformin on complications in overweight patients with type 2 diabetes［J］. Lancet, 1998, 352: 854-865.
［14］Clark CM Jr. The burden of chronic hyperglycemia［J］. Diabtes Care, 1998, 21(suppl3): 32-34.
［15］Petitti D. Meta-analysis, decision analysis, and cost-effectiveness analysis［J］. 2nd ed. New York: Oxford University Press, 2000, 141-168.
［16］杨硕, 姜晓笛. 利格列汀联合门冬胰岛素50治疗肝源性糖尿病的效果观察［J］. 临床肝胆病杂志, 2017, 33(5): 928-931.
［17］付兴. 肠促胰素的应用与急、慢性胰腺炎发生风险的相关性研究［J］. 临床肝胆病杂志, 2017, 33(1): 35.
［18］Rizza RA. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy［J］. Diabetes, 2010, 59(11): 697-707.
［19］Jung KY, Kim KM, Lim S. Therapeutic approaches for preserving or restoring pancreatic β-cell function and mass［J］. Diabetes Metab J, 2014, 38(6): 426-436.
［20］D'Alessio DA, Denney AM, Hermiller LM, et al. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes［J］. J Clin Endocrinol Metab, 2009, 94(1): 81-88.
［21］DeFronzo RA, Fleck PR, Wilson CA, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study［J］. Diabetes Care, 2008, 31(12): 2315-2317.
［22］Del PS, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial［J］. Diabetes Obes Metab, 2011, 13(3): 258-267.
［23］Morita A, Mukai E, Hiratsuka A, et al. Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function［J］. Endocrine, 2016, 51(3): 1-11.

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[3]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[4]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[5]	DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian. Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284.
[6]	XU Yongxia, XIE Mingzhu, GONG Muxue, HUANG Jiaying, ZHAO Li, ZHU Defa. Effects of 25(OH)D on islet β-cells function in the elderly with type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1021-1026.
[7]	ZHAO Hailing, ZHANG Haojun, ZHAO Tingting, YAN Meihua, DONG Xi, MA Liang, LI Ping. Association between the polymorphism of PNPLA2 gene and the risk of ischemic stroke in type 2 diabetic patients in Chinese Han Population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 664-669.
[8]	YE Shengkai, WEN Jie, LIU Weiping, REN Xia, CHEN Haiying, DU Ying, LI Xue, ZHANG Ru, YU Li, ZHANG Biying. Effects of dapagliflozin on intima-medial thickness of carotid artery in type 2 diabetic mellitus patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 814-819.
[9]	WEI Liuping, WU Qing, YIN Nange, YANG Bin, MAO Jinxiao. Effect and safety of lactoferrin for prevention of late-onset sepsis in premature neonates: a systematic review [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 653-660.
[10]	WU Jiaqi, YANG Qiaowen, CHEN Xiumin, HUANG Runyue, HUANG Qingchun, ZHAO Yue, WU Xiaodong. Efficacy and safety of iguratimod combined with methotrexate in rheumatoid arthritis: A systematic review and Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1132-1140.
[11]	SONG Meiqing. Effect of metformin on bone mineral density, insulin resistance and cytokines in type 2 diabetes mellitus patients with primary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 694-698.
[12]	LIU Chang, JIANG Daoli, LIU Xiaofang, XU Jia, WANG Lijue, WANG Qian, XU Ling, FANG Yi. Establishment of rat model of type 2 diabetes induced by streptozotocin combined with cerebral ischemic reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 518-525.
[13]	NI Yingqun, XIE Fengtao, FANG Zhaohui. Danzhijiangtang capsule protects vasculopathy of T2DM: an evaluation based on the expression of Wnt/β-catenin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 531-537.
[14]	WANG Chanyue, WANG Ye, ZHANG Peipei, CHEN Mingyue, YANG Hao, ZHU Manli, LI Linlin. Relationship of Fusobacterium nucleatum levels in gut microbiota with type 2 diabetes mellitus in Uygurs of Xinjiang [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1321-1325.
[15]	KONG Xiang, HUA Qiang, MENG Xiangjian, YAO Xinming, WANG Yong, XIA Libin. Clinical implications of circulating miRNA-101 expression level in patients with newly diagnosed type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1406-1409.